CASI Pharmaceuticals, Inc.

NasdaqCM:CASI Stock Report

Market Cap: US$40.0m

CASI Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

CASI Pharmaceuticals's earnings have been declining at an average annual rate of -1.4%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 51.9% per year.

Key information

-1.4%

Earnings growth rate

9.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate51.9%
Return on equity-78.7%
Net Margin-95.6%
Next Earnings Update01 Apr 2024

Recent past performance updates

Recent updates

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Sep 02
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

May 20
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

CASI Pharmaceuticals Q2 2022 Earnings Preview

Aug 11

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16
Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth

Feb 18
Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth

How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?

Jan 23
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?

Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?

Dec 28
Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?

CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer

Dec 23

CASI Pharmaceuticals appoints Weihao Xu as CFO

Dec 16

Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%

Dec 02
Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%

The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares

Nov 27
The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares

Casi Pharmaceuticals jumps 6% after CEO buys 227.5K shares

Nov 25

Juventas initiates registration study for CNCT19

Nov 19

CASI Pharmaceuticals EPS misses by $0.08, beats on revenue

Nov 09

Revenue & Expenses Breakdown
Beta

How CASI Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CASI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2342-404212
30 Jun 2344-414213
31 Mar 2342-383915
31 Dec 2243-413816
30 Sep 2237-273916
30 Jun 2235-323915
31 Mar 2233-313913
31 Dec 2130-373814
30 Sep 2126-453514
30 Jun 2122-523414
31 Mar 2117-543014
31 Dec 2015-482711
30 Sep 2012-472710
30 Jun 2010-40299
31 Mar 208-463010
31 Dec 194-46309
30 Sep 193-432711
30 Jun 190-422511
31 Mar 190-322210
31 Dec 180-27189
30 Sep 180-23149
30 Jun 180-1678
31 Mar 180-1348
31 Dec 170-1147
30 Sep 170-845
30 Jun 170-845
31 Mar 170-954
31 Dec 160-954
30 Sep 160-844
30 Jun 160-844
31 Mar 160-734
31 Dec 150-744
30 Sep 150-743
30 Jun 150-2743
31 Mar 150-2743
31 Dec 140-2643
30 Sep 140-2642
30 Jun 140-632
31 Mar 140-633
31 Dec 130-633
30 Sep 131-532
30 Jun 131-532
31 Mar 131-1322

Quality Earnings: CASI is currently unprofitable.

Growing Profit Margin: CASI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of 1.4% per year.

Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: CASI has a negative Return on Equity (-78.73%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.